Zymeworks is pleased to announce, along with their partners Jazz Pharmaceuticals and BeiGene, new and updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the… Read More
VICTORIA, BC — /CNW/ — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that… Read More
First Numinus Network™ partner enters into agreement Recent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned to provide psychedelic-assisted therapy insurance reimbursement, as a result… Read More
VANCOUVER, BC — Clinical Trials BC is pleased to announce the recipients of their annual awards: the Leadership & Advocacy Award and the Service & Support Award. Watch the awards… Read More
CA$701 million co-investment to strengthen capabilities and infrastructure for drug development, manufacturing, and clinical research in Canada AbCellera to build state-of-art facilities and technologies capable of developing new antibody medicines… Read More
